drugset / Trial / NCT01665937
STA-9090 in Patients With Advanced Hepatocellular Cancer
Phase 1
Completed
16 enrolled
Massachusetts General Hospital
Beth Israel Deaconess Medical Center · collabDana-Farber Cancer Institute · collabSynta Pharmaceuticals Corp. · collab
NaSingle-groupOpen-labelTreatment
Summary
STA-9090 works by inhibiting the function of a protein in tumor cells called Hsp90. Hsp90 is thought to play a role in tumor growth. By interfering with this protein's function, STA-9090 may help kill tumor cells. This drug has been used in other research studies and information from those studies suggests that this agent may help to slow tumor growth in HCC. The purpose of this research study is to find the highest dose of STA-9090 that can safely be given to participants with advanced HCC. The investigators will also get more information about the safety of STA-9090 and perform tests to learn more about how STA-9090 affects the body.
Timeline
- Start
- 2010-08
- Primary completion
- 2013-07
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ganetespib | Small molecule | — | Intravenous |